AI Tokens
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Johnson & Johnson, historical price multiples (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Price to earnings (P/E) 38.56 29.70 25.87 21.66 18.51 18.02 17.14 26.92 27.19 10.11 9.46 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95
Price to operating profit (P/OP) 25.09 24.10 21.40 22.95 19.83 19.04 17.74 18.20 18.65 17.54 16.96 17.78 15.69 18.91 18.26 17.62 19.64 20.45 21.06
Price to sales (P/S) 6.25 6.38 5.65 6.16 5.04 4.51 4.19 4.26 4.55 4.44 4.25 4.43 4.01 4.84 4.60 4.34 4.69 4.80 5.00
Price to book value (P/BV) 7.61 7.35 6.70 7.12 5.86 5.20 4.79 5.30 5.69 5.37 5.20 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


The valuation ratios exhibit a period of significant volatility between 2022 and 2024, followed by a consistent upward trajectory in valuation multiples through late 2026. A notable contraction in multiples occurred during the latter half of 2023, characterized by a sharp decline in the price-to-earnings ratio.

Price to Earnings (P/E) Ratio
The P/E ratio demonstrates the highest degree of volatility among the analyzed metrics. After reaching 33.43 in April 2023, the ratio plummeted to a low of 9.46 by March 2024. A substantial recovery began in the second half of 2024, with the ratio climbing steadily to reach a peak of 38.56 by September 2026. This movement suggests a dramatic shift in market sentiment or a significant adjustment in earnings relative to share price during the 2023-2024 window.
Price to Operating Profit (P/OP) Ratio
The P/OP ratio remained more stable than the P/E ratio but followed a similar directional trend. It reached a trough of 15.69 in October 2023 before initiating a gradual ascent, concluding the period at 25.09. The lower volatility of this ratio compared to the P/E ratio suggests that operating profitability was more consistent than net income.
Price to Sales (P/S) Ratio
Price-to-sales multiples remained largely range-bound between 4.01 and 5.00 from April 2022 through March 2025. However, a distinct expansion occurred starting in June 2025, with the ratio increasing to a high of 6.38 in June 2026. This indicates that the market began assigning a higher premium to each dollar of revenue generated during the final phase of the analyzed period.
Price to Book Value (P/BV) Ratio
The P/BV ratio displayed a mid-term decline, reaching a minimum of 4.79 in March 2025. Following this low, there was a consistent increase in the multiple, rising to 7.61 by September 2026. This expansion reflects an increasing gap between the market valuation and the accounting book value of assets.

Overall, the valuation profile transitioned from a period of compression in 2023 to a strong expansion phase in 2025 and 2026. The synchronized rise in P/E, P/S, and P/BV ratios during the final six quarters indicates a comprehensive rerating of the stock's market value.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Earnings (P/E)

Johnson & Johnson, historical P/E calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1 2,407,310,266 2,409,898,597 2,407,216,971 2,409,898,936 2,409,295,102 2,408,338,872 2,406,073,279 2,407,616,693 2,407,622,972 2,407,243,667 2,406,679,183 2,408,767,228 2,407,278,620 2,598,969,594 2,598,734,075 2,604,286,303 2,614,483,607 2,629,179,895 2,631,401,804
Selected Financial Data (US$)
Net earnings (loss) (in millions) 210 5,534 5,235 5,116 5,152 5,537 10,999 3,431 2,694 4,686 3,255 4,049 26,028 5,144 (68) 3,520 4,458 4,814 5,149
Earnings per share (EPS)2 6.69 8.73 8.74 11.12 10.43 9.41 9.06 5.84 6.10 15.79 15.99 14.59 14.38 5.02 4.90 6.89 7.33 6.99 7.54
Share price1, 3 257.78 259.27 226.10 240.86 192.94 169.56 155.38 157.25 165.86 159.64 151.18 156.55 145.60 167.53 163.70 158.24 172.31 174.52 180.46
Valuation Ratio
P/E ratio4 38.56 29.70 25.87 21.66 18.51 18.02 17.14 26.92 27.19 10.11 9.46 10.73 10.12 33.35 33.43 22.97 23.52 24.98 23.95
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. — 68.64 97.96 94.06 159.78 92.57 77.73 79.59 69.16 62.04 48.26 63.84 38.27 30.55 34.43 22.62 19.16 19.44 21.64
Amgen Inc. — 25.22 22.82 25.81 24.59 23.15 25.49 38.24 40.68 53.65 44.38 23.14 18.09 16.31 16.18 19.56 21.00 20.03 22.23
Bristol-Myers Squibb Co. 13.58 14.27 17.01 17.30 15.38 17.46 18.29 — — — — 12.27 13.01 15.93 19.43 23.97 23.71 24.14 25.64
Danaher Corp. 37.99 31.43 37.32 40.93 44.52 39.84 36.51 38.12 48.49 45.39 42.59 39.09 24.76 29.99 25.00 25.65 26.65 32.73 32.15
Eli Lilly & Co. 46.86 41.23 34.82 47.45 43.36 43.95 67.76 77.63 96.05 109.42 120.94 135.24 110.43 76.21 65.16 50.08 55.53 51.05 45.29
Gilead Sciences Inc. — — 18.06 21.54 18.18 21.68 20.62 296.57 925.87 89.29 166.76 16.17 17.10 17.88 17.75 22.68 29.30 18.66 17.25
Merck & Co. Inc. — 99.98 31.27 16.79 11.00 12.30 11.98 13.49 20.98 20.73 140.05 893.99 56.85 86.53 22.92 19.21 16.41 13.36 15.70
Pfizer Inc. — 33.42 20.12 19.83 14.06 13.09 17.22 18.42 37.00 — — 73.42 16.60 9.42 7.44 7.58 8.81 9.56 11.11
Regeneron Pharmaceuticals Inc. — 17.56 16.27 18.19 15.03 13.29 13.65 17.76 19.79 27.88 26.78 25.99 22.35 19.48 19.77 19.68 14.98 11.67 9.15
Thermo Fisher Scientific Inc. — 30.48 25.46 28.82 32.45 26.56 24.55 32.03 34.78 37.81 36.21 35.65 29.57 37.01 34.99 30.55 27.64 31.09 28.15
Vertex Pharmaceuticals Inc. — 27.54 24.83 31.58 29.11 26.43 — — — — 26.34 30.42 28.09 27.49 27.34 23.02 24.62 23.12 26.50

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q3 2026 Calculation
EPS = (Net earnings (loss)Q3 2026 + Net earnings (loss)Q2 2026 + Net earnings (loss)Q1 2026 + Net earnings (loss)Q4 2025) ÷ No. shares of common stock outstanding
= (210,000,000 + 5,534,000,000 + 5,235,000,000 + 5,116,000,000) ÷ 2,407,310,266 = 6.69

3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.

4 Q3 2026 Calculation
P/E ratio = Share price ÷ EPS
= 257.78 ÷ 6.69 = 38.56

5 Click competitor name to see calculations.


The valuation metrics for the period between April 2022 and September 2026 exhibit significant volatility, characterized by fluctuating correlations between share price movements and earnings performance.

Earnings-Driven Valuation Contraction
A pronounced contraction in the P/E ratio is observed between October 2023 and June 2024, during which the ratio reached a period low of 9.46. This compression was primarily driven by a substantial increase in Earnings Per Share (EPS), which climbed from 7.33 in late 2022 to a peak of 15.99 in March 2024, while share prices remained relatively stagnant in the 145.60 to 159.64 range.
Price-Driven Valuation Expansion
Beginning in March 2025, a steady upward trend in the P/E ratio emerged, rising from 17.14 to 21.66 by December 2025. This expansion was fueled by aggressive share price appreciation, with the price increasing from 155.38 to 240.86, effectively outpacing the growth in quarterly earnings.
Terminal Valuation Acceleration
The final phase of the analysis, spanning March 2026 to September 2026, shows a sharp acceleration in the P/E ratio, which peaked at 38.56. This spike occurred concurrently with a decline in EPS from 8.74 down to 6.69, indicating a significant divergence where the market valuation expanded despite deteriorating quarterly earnings.
Overall Trend Summary
The data reveals a shift from a value-oriented pricing phase in 2023 and early 2024 to a high-premium valuation phase by late 2026. The P/E ratio transitioned from a state of extreme compression (sub-10) to a state of significant expansion (above 38), reflecting a change in investor sentiment or anticipated future growth that decoupled from current earnings output.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Operating Profit (P/OP)

Johnson & Johnson, historical P/OP calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1 2,407,310,266 2,409,898,597 2,407,216,971 2,409,898,936 2,409,295,102 2,408,338,872 2,406,073,279 2,407,616,693 2,407,622,972 2,407,243,667 2,406,679,183 2,408,767,228 2,407,278,620 2,598,969,594 2,598,734,075 2,604,286,303 2,614,483,607 2,629,179,895 2,631,401,804
Selected Financial Data (US$)
Operating earnings (in millions) 5,845 7,140 6,327 5,426 7,033 6,646 6,182 3,582 5,037 6,276 5,909 4,193 5,534 5,813 5,667 5,331 6,216 6,087 5,748
Operating profit per share2 10.28 10.76 10.56 10.49 9.73 8.91 8.76 8.64 8.89 9.10 8.91 8.80 9.28 8.86 8.97 8.98 8.78 8.53 8.57
Share price1, 3 257.78 259.27 226.10 240.86 192.94 169.56 155.38 157.25 165.86 159.64 151.18 156.55 145.60 167.53 163.70 158.24 172.31 174.52 180.46
Valuation Ratio
P/OP ratio4 25.09 24.10 21.40 22.95 19.83 19.04 17.74 18.20 18.65 17.54 16.96 17.78 15.69 18.91 18.26 17.62 19.64 20.45 21.06
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. — 25.67 23.23 26.37 42.20 31.76 32.37 37.26 25.63 26.99 22.62 24.34 16.55 15.26 16.15 14.78 14.52 14.12 14.57
Amgen Inc. — 19.30 16.84 21.92 19.86 18.71 20.31 21.55 27.68 27.12 23.97 19.69 15.45 13.71 14.25 13.40 14.89 14.08 15.88
Bristol-Myers Squibb Co. 10.86 11.30 12.42 12.20 10.25 11.07 13.65 — — — — 13.53 14.14 16.24 17.09 18.29 17.79 18.62 20.32
Danaher Corp. 31.53 24.54 28.93 31.54 33.80 30.79 28.49 30.56 39.52 38.14 37.52 35.64 23.61 27.01 21.31 20.97 20.71 25.91 26.48
Eli Lilly & Co. 37.05 32.74 27.92 37.24 34.60 35.19 53.43 63.73 79.30 88.66 99.34 109.75 93.27 69.42 59.60 43.88 46.48 39.20 36.49
Gilead Sciences Inc. — — 16.05 18.29 14.06 17.00 14.96 85.65 143.05 36.80 51.26 12.05 12.16 11.57 11.21 14.21 16.27 11.02 10.78
Merck & Co. Inc. — 49.74 23.37 14.44 9.67 10.57 10.37 11.60 18.67 18.41 75.94 138.56 33.75 44.67 18.53 15.55 13.85 11.72 14.29
Pfizer Inc. — 10.48 10.37 10.82 10.07 9.49 11.27 11.92 27.24 — — 121.63 17.49 9.17 6.74 6.80 7.82 9.11 11.49
Regeneron Pharmaceuticals Inc. — 19.78 19.83 22.90 18.65 15.42 16.03 19.63 23.18 30.86 26.82 25.39 21.13 19.32 18.68 18.01 12.91 9.68 7.98
Thermo Fisher Scientific Inc. — 26.07 22.09 24.94 28.40 23.62 21.64 27.65 29.74 32.66 31.40 31.16 25.59 31.55 29.54 25.30 21.43 23.99 21.84
Vertex Pharmaceuticals Inc. — 25.40 23.01 29.92 26.79 24.50 — — — — 25.25 28.74 25.14 23.33 22.03 17.75 19.41 18.11 22.13

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q3 2026 Calculation
Operating profit per share = (Operating earningsQ3 2026 + Operating earningsQ2 2026 + Operating earningsQ1 2026 + Operating earningsQ4 2025) ÷ No. shares of common stock outstanding
= (5,845,000,000 + 7,140,000,000 + 6,327,000,000 + 5,426,000,000) ÷ 2,407,310,266 = 10.28

3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.

4 Q3 2026 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 257.78 ÷ 10.28 = 25.09

5 Click competitor name to see calculations.


The analysis of the price to operating profit (P/OP) ratio reveals three distinct phases of valuation movement between April 2022 and September 2026. Throughout this period, the share price exhibited significantly higher volatility than the underlying operating profit per share, which maintained a steady, gradual upward trajectory.

Share Price and Operating Profit Dynamics
The share price experienced a period of decline and consolidation from April 2022 (180.46) to October 2023 (145.60), followed by a robust recovery and expansion that peaked at 259.27 in June 2026. Conversely, operating profit per share remained relatively stable, rising incrementally from 8.57 in April 2022 to 10.76 in June 2026. This divergence indicates that fluctuations in the P/OP ratio were driven primarily by market pricing rather than operational volatility.
P/OP Ratio Trajectory
The P/OP ratio followed a U-shaped trend. An initial contraction occurred between April 2022 and October 2023, with the ratio falling from 21.06 to a period low of 15.69. A phase of stabilization followed through 2024, with the ratio oscillating between 16.96 and 18.65. Beginning in mid-2025, a sharp expansion phase emerged, driving the ratio from 19.04 in March 2025 to a peak of 25.09 by September 2026.
Valuation Insights
The substantial increase in the P/OP ratio during 2025 and 2026 suggests a significant expansion in the valuation multiple. Because the share price rose at a rate far exceeding the growth in operating profit per share during this window, the market attributed a higher premium to the company's operating earnings. The transition from a ratio of 15.69 in late 2023 to 25.09 in late 2026 represents a marked shift in investor sentiment and valuation benchmarks.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Sales (P/S)

Johnson & Johnson, historical P/S calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1 2,407,310,266 2,409,898,597 2,407,216,971 2,409,898,936 2,409,295,102 2,408,338,872 2,406,073,279 2,407,616,693 2,407,622,972 2,407,243,667 2,406,679,183 2,408,767,228 2,407,278,620 2,598,969,594 2,598,734,075 2,604,286,303 2,614,483,607 2,629,179,895 2,631,401,804
Selected Financial Data (US$)
Sales to customers (in millions) 25,399 25,310 24,062 24,564 23,993 23,743 21,893 22,520 22,471 22,447 21,383 21,395 21,351 21,519 20,894 23,706 23,791 24,020 23,426
Sales per share2 41.26 40.64 40.03 39.09 38.25 37.63 37.13 36.89 36.42 35.96 35.59 35.35 36.34 34.59 35.56 36.46 36.73 36.36 36.06
Share price1, 3 257.78 259.27 226.10 240.86 192.94 169.56 155.38 157.25 165.86 159.64 151.18 156.55 145.60 167.53 163.70 158.24 172.31 174.52 180.46
Valuation Ratio
P/S ratio4 6.25 6.38 5.65 6.16 5.04 4.51 4.19 4.26 4.55 4.44 4.25 4.43 4.01 4.84 4.60 4.34 4.69 4.80 5.00
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. — 6.73 5.67 6.50 6.40 5.97 5.68 6.04 6.38 6.02 5.32 5.72 4.52 4.74 4.60 4.61 4.44 4.28 4.76
Amgen Inc. — 6.08 5.02 5.66 4.99 4.57 4.61 4.88 5.53 5.68 5.93 5.78 5.34 5.14 5.14 5.17 5.85 5.35 5.21
Bristol-Myers Squibb Co. 2.51 2.69 2.55 2.53 1.93 1.85 2.08 2.36 2.38 2.20 1.99 2.19 2.40 2.81 3.10 3.29 3.39 3.39 3.41
Danaher Corp. 6.42 5.01 5.56 6.02 6.43 5.66 5.77 6.23 7.95 8.10 7.90 7.76 5.63 6.77 5.76 5.79 5.66 6.59 6.68
Eli Lilly & Co. 14.95 13.82 12.18 15.03 13.44 11.39 15.36 18.25 19.67 20.64 20.66 20.77 17.18 16.78 13.38 10.96 11.46 9.99 9.47
Gilead Sciences Inc. — 5.44 5.69 6.34 5.16 4.76 4.31 4.98 4.18 3.41 2.97 3.40 3.69 3.61 3.70 3.86 3.64 2.84 2.86
Merck & Co. Inc. — 4.77 4.25 4.71 3.26 3.17 3.27 3.60 4.03 4.56 5.26 5.43 4.42 4.62 5.16 4.71 4.25 3.87 4.12
Pfizer Inc. — 2.27 2.38 2.46 2.20 2.20 2.17 2.32 2.60 3.00 2.86 2.61 2.51 2.58 2.32 2.37 2.63 2.77 3.00
Regeneron Pharmaceuticals Inc. — 4.89 4.82 5.71 4.83 4.17 4.36 5.52 6.65 8.93 7.89 7.84 6.81 6.61 6.69 7.01 5.87 4.66 4.40
Thermo Fisher Scientific Inc. — 4.58 3.86 4.34 4.87 4.05 3.73 4.73 5.04 5.55 5.14 4.99 4.05 4.87 4.81 4.73 4.40 5.40 5.20
Vertex Pharmaceuticals Inc. — 9.64 8.82 10.40 9.13 8.42 10.41 10.78 12.12 12.35 10.39 11.16 10.10 9.73 9.68 8.56 9.26 8.85 8.17

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q3 2026 Calculation
Sales per share = (Sales to customersQ3 2026 + Sales to customersQ2 2026 + Sales to customersQ1 2026 + Sales to customersQ4 2025) ÷ No. shares of common stock outstanding
= (25,399,000,000 + 25,310,000,000 + 24,062,000,000 + 24,564,000,000) ÷ 2,407,310,266 = 41.26

3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.

4 Q3 2026 Calculation
P/S ratio = Share price ÷ Sales per share
= 257.78 ÷ 41.26 = 6.25

5 Click competitor name to see calculations.


An analysis of the valuation metrics from April 2022 through September 2026 reveals a distinct transition from a period of valuation stability to a phase of significant expansion. The Price-to-Sales (P/S) ratio experienced moderate volatility in the first three years before entering a strong upward trend starting in mid-2025.

Share Price Dynamics
The share price exhibited a downward trajectory throughout 2022, declining from 180.46 US$ to 158.24 US$. This was followed by a period of consolidation between 2023 and 2024, where the price largely fluctuated between 145.60 US$ and 167.53 US$. A sharp reversal occurred in 2025, characterized by rapid growth that peaked at 259.27 US$ in June 2026, representing a substantial increase in market valuation.
Sales per Share Trends
Revenue efficiency remained relatively stagnant from April 2022 through December 2024, oscillating within a narrow band between 34.59 US$ and 36.89 US$. However, beginning in early 2025, a consistent quarterly growth pattern emerged. Sales per share rose steadily from 37.13 US$ in March 2025 to 41.26 US$ by September 2026, indicating a gradual and sustained improvement in top-line performance per share.
Price-to-Sales (P/S) Ratio Interpretation
The P/S ratio remained range-bound between 4.01 and 5.00 from April 2022 until June 2025, suggesting that the market valuation was closely aligned with sales performance during this interval. The lowest valuation multiple of 4.01 was recorded in October 2023. A significant shift in valuation occurred in the latter half of 2025 and throughout 2026, with the ratio climbing to a peak of 6.38 in June 2026. This expansion indicates that the share price appreciated at a rate significantly exceeding the growth in sales per share, reflecting an increase in the premium investors were willing to pay for each dollar of revenue.

The divergence between the steady growth of sales per share and the aggressive acceleration of the share price since 2025 suggests a fundamental shift in market sentiment or an anticipation of higher future growth rates, resulting in a permanently higher valuation floor for the P/S ratio compared to the 2022-2024 period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Book Value (P/BV)

Johnson & Johnson, historical P/BV calculation (quarterly data)

Microsoft Excel
Sep 27, 2026 Jun 28, 2026 Mar 29, 2026 Dec 28, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 29, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
No. shares of common stock outstanding1 2,407,310,266 2,409,898,597 2,407,216,971 2,409,898,936 2,409,295,102 2,408,338,872 2,406,073,279 2,407,616,693 2,407,622,972 2,407,243,667 2,406,679,183 2,408,767,228 2,407,278,620 2,598,969,594 2,598,734,075 2,604,286,303 2,614,483,607 2,629,179,895 2,631,401,804
Selected Financial Data (US$)
Total Johnson & Johnson shareholders’ equity (in millions) 81,529 84,971 81,186 81,544 79,277 78,473 78,109 71,490 70,158 71,538 70,020 68,774 71,228 75,149 70,869 76,804 74,599 76,357 74,709
Book value per share (BVPS)2 33.87 35.26 33.73 33.84 32.90 32.58 32.46 29.69 29.14 29.72 29.09 28.55 29.59 28.91 27.27 29.49 28.53 29.04 28.39
Share price1, 3 257.78 259.27 226.10 240.86 192.94 169.56 155.38 157.25 165.86 159.64 151.18 156.55 145.60 167.53 163.70 158.24 172.31 174.52 180.46
Valuation Ratio
P/BV ratio4 7.61 7.35 6.70 7.12 5.86 5.20 4.79 5.30 5.69 5.37 5.20 5.48 4.92 5.79 6.00 5.37 6.04 6.01 6.36
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. — — — — — — 229.63 102.40 58.73 48.87 36.12 29.97 20.61 20.62 19.68 15.52 16.06 16.76 16.59
Amgen Inc. — 18.86 19.37 22.99 17.91 20.63 24.36 26.61 22.86 28.34 33.25 24.94 17.87 19.19 23.95 35.01 39.30 54.46 138.87
Bristol-Myers Squibb Co. 5.36 5.94 6.17 6.61 5.01 5.06 5.70 6.98 6.60 6.01 5.49 3.35 3.72 3.97 4.46 4.88 4.85 4.90 5.07
Danaher Corp. 3.07 2.39 2.60 2.82 3.05 2.60 2.70 3.00 3.68 3.82 3.51 3.47 2.78 3.65 3.33 3.64 3.77 4.36 4.36
Eli Lilly & Co. 32.09 32.51 28.21 36.91 33.55 33.19 47.74 57.93 56.45 59.24 57.94 65.80 49.10 44.75 33.11 29.36 33.27 34.00 29.75
Gilead Sciences Inc. — 13.72 7.08 8.07 6.85 6.96 6.42 7.36 6.36 5.15 4.61 4.01 4.50 4.63 4.72 4.90 4.63 3.82 3.91
Merck & Co. Inc. — 7.57 6.09 5.82 4.04 4.12 4.32 4.99 5.73 6.53 8.00 8.68 6.35 6.96 6.38 6.07 5.63 5.12 5.44
Pfizer Inc. — 1.70 1.67 1.78 1.49 1.59 1.50 1.68 1.70 1.92 1.74 1.75 1.80 2.04 2.14 2.48 2.83 3.21 3.37
Regeneron Pharmaceuticals Inc. — 2.40 2.29 2.62 2.22 1.98 2.09 2.67 3.14 4.27 3.83 3.96 3.58 3.49 3.52 3.77 3.75 3.21 3.65
Thermo Fisher Scientific Inc. — 4.03 3.36 3.62 4.18 3.46 3.24 4.09 4.36 4.96 4.80 4.57 3.88 4.84 4.99 4.83 4.46 5.47 5.23
Vertex Pharmaceuticals Inc. — 5.99 5.56 6.69 6.18 5.60 7.01 7.24 8.24 8.64 5.71 6.26 5.90 5.98 6.18 5.50 6.18 6.19 5.95

Based on: 10-Q (reporting date: 2026-09-27), 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-28), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-29), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Data adjusted for splits and stock dividends.

2 Q3 2026 Calculation
BVPS = Total Johnson & Johnson shareholders’ equity ÷ No. shares of common stock outstanding
= 81,529,000,000 ÷ 2,407,310,266 = 33.87

3 Closing price as at the filing date of Johnson & Johnson Quarterly or Annual Report.

4 Q3 2026 Calculation
P/BV ratio = Share price ÷ BVPS
= 257.78 ÷ 33.87 = 7.61

5 Click competitor name to see calculations.


The Price to Book Value (P/BV) ratio exhibits a cyclical trajectory characterized by an initial period of valuation compression followed by a significant expansion in the latter half of the observed period. The ratio fluctuated from a high of 6.36 in April 2022 to a low of 4.79 in December 2024, before climbing to a peak of 7.61 by September 2026.

Valuation Compression and Volatility (April 2022 – December 2024)
A general downward trend in the P/BV ratio is observed during this interval. The ratio declined from 6.36 to 4.79, driven primarily by a contraction in the share price, which fell from 180.46 to 157.25. During this phase, the Book Value Per Share (BVPS) remained relatively stagnant, fluctuating within a narrow band between 27.27 and 29.72, suggesting that the valuation decline was a result of market sentiment or pricing adjustments rather than a deterioration of the underlying book value.
Valuation Expansion (March 2025 – September 2026)
A strong upward trend is evident starting in March 2025, with the P/BV ratio increasing from 5.20 to 7.61. This expansion is attributed to a substantial rally in the share price, which rose from 155.38 in December 2024 to 257.78 by September 2026. The market premium applied to the book value increased significantly, indicating heightened investor confidence or an increase in the perceived value of the company's intangible assets and future earnings potential.
Book Value Per Share (BVPS) Growth
While the share price drove the primary volatility of the P/BV ratio, a structural shift in BVPS is noted beginning in March 2025. The BVPS moved from a historical range of sub-30.00 levels to a higher plateau between 32.46 and 35.26. Despite this increase in the equity base, the share price grew at a disproportionately faster rate, resulting in the observed escalation of the P/BV ratio toward the end of the period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?